Cognition Therapeutics Inc CGTX
We take great care to ensure that the data presented and summarized in this overview for COGNITION THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CGTX
View all-
Bios Capital Management, LP Fort Worth, TX6MShares$9.3 Million9.11% of portfolio
-
Davenport & CO LLC2.69MShares$4.17 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.68MShares$4.16 Million0.0% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$3.42 Million0.02% of portfolio
-
Tang Capital Management LLC San Diego, CA1.2MShares$1.86 Million0.07% of portfolio
-
Chescapmanager LLC Baltimore, MD997KShares$1.55 Million0.14% of portfolio
-
Jane Street Group, LLC New York, NY926KShares$1.44 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny714KShares$1.11 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA713KShares$1.1 Million0.0% of portfolio
-
Hilton Capital Management, LLC581KShares$900,7820.07% of portfolio
Latest Institutional Activity in CGTX
Top Purchases
Top Sells
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Insider Transactions at CGTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2025
|
Aaron G.L. Fletcher Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,729
+12.08%
|
$0
$0.84 P/Share
|
|
Jul 29
2025
|
Lisa Ricciardi CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
23,400
-2.43%
|
$0
$0.67 P/Share
|
|
Jul 29
2025
|
Lisa Ricciardi CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+7.23%
|
-
|
|
Jul 29
2025
|
John Brendan Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,360
-2.15%
|
$0
$0.67 P/Share
|
|
Jul 29
2025
|
John Brendan Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+6.46%
|
-
|
|
Jul 29
2025
|
Anthony Caggiano Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,281
-4.19%
|
$0
$0.67 P/Share
|
|
Jul 29
2025
|
Anthony Caggiano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+11.85%
|
-
|
|
Jun 18
2025
|
Brett P Monia Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+41.21%
|
-
|
|
Jun 18
2025
|
Ellen B Richstone Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+36.76%
|
-
|
|
Jun 18
2025
|
Peggy Wallace Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+28.22%
|
-
|
|
Jun 18
2025
|
Jack A. Khattar Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+41.21%
|
-
|
|
Jun 18
2025
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
34,000
+41.21%
|
-
|
|
Jun 18
2025
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+41.21%
|
-
|
|
May 01
2025
|
John Brendan Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,692
-2.34%
|
$0
$0.45 P/Share
|
|
Feb 15
2025
|
John Brendan Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,723
-0.41%
|
$0
$0.59 P/Share
|
|
Feb 15
2025
|
Anthony Caggiano Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,296
-1.25%
|
$0
$0.59 P/Share
|
|
Feb 15
2025
|
Lisa Ricciardi CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,619
-0.74%
|
$0
$0.59 P/Share
|
|
Feb 04
2025
|
Lisa Ricciardi CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
631,300
+41.4%
|
-
|
|
Feb 04
2025
|
John Brendan Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,000
+41.48%
|
-
|
|
Feb 04
2025
|
Anthony Caggiano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,000
+41.04%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.6M shares |
|---|---|
| Exercise of conversion of derivative security | 7.73K shares |
| Open market or private purchase | 38.9K shares |
| Payment of exercise price or tax liability | 118K shares |
|---|